Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro
Title:
Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro
Author:
Bellone, Stefania Black, Jonathan English, Diana P. Schwab, Carlton L. Lopez, Salvatore Cocco, Emiliano Bonazzoli, Elena Predolini, Federica Ferrari, Francesca Ratner, Elena Silasi, Dan-Arin Azodi, Masoud Schwartz, Peter E. Santin, Alessandro D.